Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Common Equity (2016 - 2025)

UroGen Pharma's Common Equity history spans 10 years, with the latest figure at -$105.5 million for Q4 2025.

  • For Q4 2025, Common Equity fell 1098.16% year-over-year to -$105.5 million; the TTM value through Dec 2025 reached -$105.5 million, down 1098.16%, while the annual FY2025 figure was -$105.5 million, 1098.16% down from the prior year.
  • Common Equity reached -$105.5 million in Q4 2025 per URGN's latest filing, up from -$115.4 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $76.5 million in Q1 2021 to a low of -$138.4 million in Q2 2023.
  • Average Common Equity over 5 years is -$37.7 million, with a median of -$41.5 million recorded in 2022.
  • Peak YoY movement for Common Equity: tumbled 1162.18% in 2022, then surged 160.76% in 2024.
  • A 5-year view of Common Equity shows it stood at $8.4 million in 2021, then crashed by 1162.18% to -$89.4 million in 2022, then rose by 27.02% to -$65.2 million in 2023, then skyrocketed by 86.5% to -$8.8 million in 2024, then tumbled by 1098.16% to -$105.5 million in 2025.
  • Per Business Quant, the three most recent readings for URGN's Common Equity are -$105.5 million (Q4 2025), -$115.4 million (Q3 2025), and -$93.4 million (Q2 2025).